临床试验/NCT05458752

NCT05458752已完成不适用

Pneumocystis Jirovecii Pneumonia in Non-HIV-infected Immunocompromised Patients : a Prognostic Observational Retrospective Monocentre Study

Central Hospital, Nancy, France1 个研究点分布在 1 个国家目标入组 133 人开始时间: 2020年4月1日最近更新: 2023年7月5日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方
入组人数: 133
试验地点: 1
主要终点: Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

Pneumocystis jirovecii pneumonia (PjP) is a rare infectiouse disease with a high level of mortality. PjP is a classical opportunistic infection which concern HIV infected and immunocompromised patients. During the past decade, several therapeutic's progresses have been done in oncology, immunology and hematology. As a consequence, patients benefited of greater treatment efficacy but are exposed to a higher risk of opportunistic infections as PjP. The investigators hypothesis is that PjP incidence increase and its form is depending of underlying immune conditions. The investigators aim to describe its incidence, the PjP forms depending on comorbidities and to identifiy pronostics factors.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

性别: All
接受健康志愿者: 否

入选标准

•Underlying immune condition at risk of Pneumocystis jirovecii pneumonia excluding HIV infection
•Clinical, biological and radiological presentation which evoke Pneumocystis jirovecii pneumonia
•Microbiological confirmation by respiratory specimen analyses ( specific coloration and/or IFI and/or PRC)

排除标准

•No microbiological confirmation by respiratory specimen analyses
•Proved HIV infection
•Patient denied to particpate

结局指标

主要结局

Incidence of Pneumocystis jirovecii pneumonia in HIV-free patients

时间窗: Between the first january 2004 and the 31th december 2021

Number of cases / number of patients treated for a predisposing disease (heamotological or imunological disease, or cancer...)

次要结局

To describe the albumin level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the immunoglobulin level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the immunofluorescence value of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the use of pentamidine for HIV free patients with Pneumocystis carinii pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the age of giv free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the WBC level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the body mass index of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the Charlson comorbidity index of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe clinical features of Pneumocystis jirovecci pneumonia in HIV-free patients(Between the first january 2004 and the 31th december 2021)
To describe the date of the first symptoms of Pneumocystis jirovecci pneumonia in HIV-free patients(Between the first january 2004 and the 31th december 2021)
To describe the comoribidites of HIV-free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the PCR level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the previous medications used by HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the pO2 level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the creatinine level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the LDH level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the lymphocytes level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the PCR pneumocystis level of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the specific coloration value of HIV free patients with Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the use of nasal canula in HIV free patient with a Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the use of high flow oxygenation in HIV free patient with a Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the use of mechanical ventilation in HIV free patient with a Pneumocystis jirovecci pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the duration of hospitalisation of HIV free patients with Pneumocystis carinii pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the use of cotrimoxazole for HIV free patients with Pneumocystis carinii pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the use of atovaquone for HIV free patients with Pneumocystis carinii pneumonia(Between the first january 2004 and the 31th december 2021)
To describe the use of steroïd for HIV free patients with Pneumocystis carinii pneumonia(Between the first january 2004 and the 31th december 2021)

研究者

发起方

Central Hospital, Nancy, France

申办方类型

Other

责任方

Principal Investigator

主要研究者

LEFEVRE Benjamin

Doctor

Central Hospital, Nancy, France

研究点 (1)

Loading locations...

相似试验

Unknown

不适用

Pneumocystis Pneumonia Diagnosis in HIV- PatientsPneumonia, Pneumocystis

NCT02648256Rennes University Hospital1,250

Unknown

3 期

Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised PatientsPneumocystisSteroidsImmunocompromised PatientHematologic NeoplasmsImmunosuppressive AgentsNeoplasms

NCT02944045Assistance Publique - Hôpitaux de Paris222

已完成

不适用

Pneumocystis Primary Infection in Non-immunosuppressed InfantsPulmonary DiseasesFever

NCT03740646University Hospital, Brest400

招募中

不适用

Factors Associated With Survival in Patients Having Pneumocystis JiroveciiPneumocystis Jirovecii Infection

NCT06173453University Hospital, Strasbourg, France300

招募中

不适用

Caspofungin for Pneumocystis Pneumonia in PLWHIV.Pneumocystis PneumoniaHIV-1-infection

NCT06691321Instituto Nacional de Enfermedades Respiratorias60